Eyebiotech
New York
About Eyebiotech
Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $130.0M
- Funding stage: M&A
- Last round: Series A (Nov 2023)
- Website: eyebiotech.com
Industries & Categories
Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/eyebiotech-34804 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.